Abstract
Antimicrobial peptides (AMPs) are in the focus of scientific research since the 1990s. In most cases, the main aim was laid on the design of AMP to kill bacteria effectively, with particular emphasis on broadband action and independency on antibiotic resistance. However, so far no approved drug on the basis of AMP has entered the market.
Our approach of constructing AMP, called synthetic anti-lipopolysaccharide peptides (SALPs), on the basis of inhibiting the inflammatory action of lipopolysaccharide (LPS, endotoxin) from Gram-negative bacteria was focused on the neutralization of the decisive toxins. These are, beside LPS from Gram-negative bacteria, the lipoproteins (LP) from Gram-positive origin. Although some of the SALPs have an antibacterial action, the most important property is the high-affinity binding to LPS and LP, whether as constituent of the bacteria or in free form which prevents the damaging inflammation, that could otherwise lead to life-threatening septic shock. Most importantly, the SALP may inhibit inflammation independently of the resistance status of the bacteria, and so far the repeated use of the peptides apparently does not cause resistance of the attacking pathogens.
In this chapter, an overview is given over the variety of possible applications in the field of fighting against severe bacterial infections, from the use in systemic infection/inflammation up to various topical applications such as anti-biofilm action and severe skin and soft tissue infections.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Andrä J, Lamata M, Martinez de Tejada G, Bartels R, Koch MHJ, Brandenburg K (2004) Cyclic antimicrobial peptides based on Limulus anti lipopolysaccharide factor for neutralization of lipopolysaccharide. Biochem Pharmacol 68(7):1297–1307. https://doi.org/10.1016/j.bcp.2004.05.054
Andrä J, Lohner K, Blondelle SE, Jerala R, Moriyon I, Koch MH, Garidel P, Brandenburg K (2005) Enhancement of endotoxin neutralization by coupling of a C12-alkyl chain to a lactoferricin-derived peptide. Biochem J 385(Pt 1):135–143. https://doi.org/10.1042/BJ20041270
Andrä J, Gutsmann T, Garidel P, Brandenburg K (2006) Mechanisms of endotoxin neutralization by synthetic cationic compounds. J Endotoxin Res 12(5):261–277. https://doi.org/10.1179/096805106X118852
Andrä J, Howe J, Garidel P, Rössle M, Richter W, Leiva-Leon J, Moriyon I, Bartels R, Gutsmann T, Brandenburg K (2007) Mechanism of interaction of optimized limulus derived cyclic peptides with endotoxins: thermodynamic, biophysical and microbiological analysis. Biochem J 406(2):297–307. https://doi.org/10.1042/BJ20070279
Barcena-Varela S, Martinez de Tejada G, Martin L, Schuerholz T, Gil-Royo AG, Fukuoka S, Goldmann T, Droemann D, Correa W, Gutsmann T, Brandenburg K, Heinbockel L (2017) Coupling killing to neutralization: combined therapy with ceftriaxone/Pep19-2.5 counteracts sepsis in rabbits. Exp Mol Med 49(6):e345. https://doi.org/10.1038/emm.2017.75
Boto A, Perez de la Lastra JM, Gonzalez CC (2018) The road from host-defense peptides to a new generation of antimicrobial drugs. Molecules 23(2). https://doi.org/10.3390/molecules23020311
Brandenburg K, Andrä J, Müller M, Koch MHJ, Garidel P (2003) Physicochemical properties of bacterial glycopolymers in relation to bioactivity. Carbohydr Res 338(23):2477–2489. https://doi.org/10.1016/j.carres.2003.08.008
Brandenburg K, David A, Howe J, Koch MHJ, Andrä J, Garidel P (2005) Temperature dependence of the binding of endotoxins to the polycationic peptides polymyxin B and its nonapeptide. Biophys J 88(3):1845–1858. https://doi.org/10.1529/biophysj.104.047944
Brandenburg K, Garidel P, Fukuoka S, Howe J, Koch MHJ, Gutsmann T, Andrä J (2010) Molecular basis for endotoxin neutralization by amphipathic peptides derived from the alpha helical cationic core region of NK lysin. Biophys Chem 150(1–3):80–87. https://doi.org/10.1016/j.bpc.2010.01.009
Brandenburg K, Howe J, Sanchez-Gomez S, Garidel P, Roessle M, Andrä J, Jerala R, Zweytick D, Lohner K, Rappolt M, Blondelle S, Moriyon I, Martinez de Tejada GM (2010b) Effective antimicrobial and anti-endotoxin activity of cationic peptides based on lactoferricin: a biophysical and microbiological study. Anti-Infect Agents Med Chem 9(1):9–22. https://doi.org/10.2174/187152110790886736
Brandenburg K, Andrä J, Garidel P, Gutsmann T (2011) Peptide- based treatment of sepsis. Appl Microbiol Biotechol 90(3):799–808. https://doi.org/10.1007/s00253-011-3185-7
Brandenburg K, Heinbockel L, Correa W, Lohner K (2016) Peptides with dual mode of action: killing bacteria and preventing endotoxin-induced sepsis. Biochim Biophys Acta 1858(5):971–979. https://doi.org/10.1016/j.bbamem.2016.01.011
Dupont A, Heinbockel L, Brandenburg K, Hornef MW (2014) Antimicrobial peptides and the enteric mucus layer act in concert to protect the intestinal mucosa. Gut Microbes 5(6):761–765. https://doi.org/10.4161/19490976.2014.972238
Dupont A, Kaconis Y, Yang I, Albers T, Woltemate S, Heinbockel L, Andersson M, Suerbaum S, Brandenburg K, Hornef MW (2015) Intestinal mucus affinity and biological activity of an orally administered antibacterial and anti-inflammatory peptide. Gut 64(2):222–232. https://doi.org/10.1136/gutjnl-2014-307150
Ferrari D, Pizzirani C, Adinolfi E, Forchap S, Sitta B, Turchet L, Falzoni S, Minelli M, Baricordi R, Di Virgilio F (2004) The antibiotic polymyxin B modulates P2X7 receptor function. J Immunol 173(7):4652–4660. https://doi.org/10.4049/jimmunol.173.7.4652
Fink MP, Warren HS (2014) Strategies to improve drug development for sepsis. Nat Rev Drug Discov 13:741. https://doi.org/10.1038/nrd4368
Fox JL (2013) Antimicrobial peptides stage a comeback. Nat Biotechnol 31:379. https://doi.org/10.1038/nbt.2572
Frykberg RG, Banks J (2015) Challenges in the treatment of chronic wounds. Adv Wound Care (New Rochelle) 4(9):560–582. https://doi.org/10.1089/wound.2015.0635
Garidel P, Brandenburg K (2009) Current understanding of polymyxin B applications in bacteraemia/sepsis therapy prevention: clinical, pharmaceutical, structural and mechanistic aspects. Antinfect Agents Med Chem 8(4):367–385
Garidel P, Andrä J, Howe J, Gutsmann T, Brandenburg K (2007) Novel antiinflammatory and antiinfective agents. Anti-infect Agents Med Chem 6(3):185–200. https://doi.org/10.2174/187152107781023647
Gutsmann T, Razquin-Olazaran I, Kowalski I, Kaconis Y, Howe J, Bartels R, Hornef M, Schürholz T, Rössle M, Sanchez-Gomez S, Moriyon I, Martinez de Tejada G, Brandenburg K (2010) New antiseptic peptides to protect against endotoxin-mediated shock. Antimicrob Agents Chemother 54(9):3817–3824. https://doi.org/10.1128/AAC.00534-10
Habersetzer F, Leboeuf C, Doffoël M, Zeisel MB, Baumert TF (2013) Synthetic anti-lipopolysaccharide peptides and hepatitis C virus infection. Exp Opin Invest Drugs 22(7):853–862. https://doi.org/10.1517/13543784.2013.794218
Hagar JA, Powell DA, Aachoui Y, Ernst RK, Miao EA (2013) Cytoplasmic LPS activates caspase-11: implications in TLR4-independent endotoxic shock. Science 341(6151):1250–1253. https://doi.org/10.1126/science.1240988
Heinbockel L, Sanchez-Gomez S, Martinez de Tejada G, Dömming S, Brandenburg J, Kaconis Y, Hornef M, Dupont A, Marwitz S, Goldmann T, Ernst M, Gutsmann T, Schürholz T, Brandenburg K (2013) Preclinical investigations reveal the broad-spectrum neutralizing activity of peptide Pep19-2.5 on bacterial pathogenicity factors. Antimicrob Agents Chemother 57(3):1480–1487. https://doi.org/10.1128/AAC.02066-12
Heinbockel L, Marwitz S, Barcena Varela S, Ferrer-Espada R, Reiling N, Goldmann T, Gutsmann T, Mier W, Schürholz T, Drömann D, Brandenburg K, Martinez de Tejada G (2015) Therapeutical administration of peptide Pep19-2.5 and ibuprofen reduces inflammation and prevents lethal sepsis. PLoS One 10(7):e0133291. https://doi.org/10.1371/journal.pone.0133291
Hilchie AL, Wuerth K, Hancock RE (2013) Immune modulation by multifaceted cationic host defense (antimicrobial) peptides. Nat Chem Biol 9(12):761–768. https://doi.org/10.1038/nchembio.1393
Howe J, Andrä J, Conde R, Iriarte M, Garidel P, Koch MHJ, Gutsmann T, Moriyon I, Brandenburg K (2007) Thermodynamic analysis of the lipopolysaccharide dependent resistance of gram-negative bacteria against polymyxin B. Biophys J 92(8):2796–2805. https://doi.org/10.1529/biophysj.106.095711
Kaconis Y, Kowalski I, Howe J, Brauser A, Richter W, Razquin-Olazaran I, Inigo-Pestana M, Garidel P, Rössle M, Martinez de Tejada G, Gutsmann T, Brandenburg K (2011) Biophysical mechanisms of endotoxin neutralization by cationic amphiphilic peptides. Biophys J 100(11):2652–2661. https://doi.org/10.1016/j.bpj.2011.04.041
Katarzyna EG, Małgorzata D (2017) Antimicrobial peptides under clinical trials. Curr Top Med Chem 17(5):620–628. https://doi.org/10.2174/1568026616666160713143331
Khare S, Dorfleutner A, Bryan NB, Yun C, Radian AD, de Almeida L, Rojanasakul Y, Stehlik C (2012) An NLRP7-containing inflammasome mediates recognition of microbial lipopeptides in human macrophages. Immunity 36(3):464–476. https://doi.org/10.1016/j.immuni.2012.02.001
Krepstakies M, Lucifora J, Nagel CH, Zeisel MB, Holstermann B, Hohenberg H, Kowalski I, Gutsmann T, Baumert TF, Brandenburg K, Hauber J, Protzer U (2012) A new class of synthetic peptide inhibitors blocks attachment and entry of human pathogenic viruses. J Infect Dis 205(11):1654–1664. https://doi.org/10.1093/infdis/jis273
Kuhlmann N, Heinbockel L, Correa W, Gutsmann T, Goldmann T, Englisch U, Brandenburg K (2018) Peptide drug stability: the anti-inflammatory drugs Pep19-2.5 and Pep19-4LF in cream formulation. Eur J Pharm Sci 115:240–247. https://doi.org/10.1016/j.ejps.2018.01.022
Mangoni ML, McDermott AM, Zasloff M (2016) Antimicrobial peptides and wound healing: biological and therapeutic considerations. Exp Dermatol 25(3):167–173. https://doi.org/10.1111/exd.12929
Martin L, De Santis R, Koczera P, Simons N, Haase H, Heinbockel L, Brandenburg K, Marx G, Schuerholz T (2015) The synthetic antimicrobial peptide 19-2.5 interacts with heparanase and heparan sulfate in murine and human sepsis. PLoS One 10(11):e0143583. https://doi.org/10.1371/journal.pone.0143583
Martin L, Horst K, Chiazza F, Oggero S, Collino M, Brandenburg K, Hildebrand F, Marx G, Thiemermann C, Schuerholz T (2016) The synthetic antimicrobial peptide 19-2.5 attenuates septic cardiomyopathy and prevents down-regulation of SERCA2 in polymicrobial sepsis. Sci Rep 6:37277. https://doi.org/10.1038/srep37277
Martínez de Tejada GM, Sanchez-Gomez S, Razquin-Olazaran I, Kowalski I, Kaconis Y, Heinbockel L, Andrä J, Schürholz T, Hornef M, Dupont A, Garidel P, Lohner K, Gutsmann T, David SA, Brandenburg K (2012) Bacterial cell wall compounds as promising targets of antimicrobial agents I. Antimicrobial Peptides and Lipopolyamines. Curr Drug Targets 13(9):1121–1130
Martinez de Tejada G, Heinbockel L, Ferrer-Espada R, Heine H, Alexander C, Barcena-Varela S, Goldmann T, Correa W, Wiesmüller KH, Gisch N, Sanchez-Gomez S, Fukuoka S, Schürholz T, Gutsmann T, Brandenburg K (2015) Lipoproteins/peptides are sepsis-inducing toxins from bacteria that can be neutralized by synthetic anti-endotoxin peptides. Sci Rep 5:14292. https://doi.org/10.1038/srep14292
Mirski T, Niemcewicz M, Bartoszcze M, Gryko R, Michalski A (2017) Utilisation of peptides against microbial infections – a review. Ann Agric Environ Med 25(2):205–210. https://doi.org/10.26444/aaem/74471
Mishra B, Reiling S, Zarena D, Wang G (2017) Host defense antimicrobial peptides as antibiotics: design and application strategies. Curr Opin Chem Biol 38:87–96. https://doi.org/10.1016/j.cbpa.2017.03.014
Molchanova N, Hansen PR, Franzyk H (2017) Advances in development of antimicrobial peptidomimetics as potential drugs. Molecules 22(9). https://doi.org/10.3390/molecules22091430
Nordström R, Malmsten M (2017) Delivery systems for antimicrobial peptides. Adv Colloid Interf Sci 242:17–34. https://doi.org/10.1016/j.cis.2017.01.005
Opal SM, Laterre P, Francois B et al (2013) Effect of eritoran, an antagonist of md2-tlr4, on mortality in patients with severe sepsis: the access randomized trial. JAMA 309(11):1154–1162. https://doi.org/10.1001/jama.2013.2194
Park KS, Choi KH, Kim YS, Hong BS, Kim OY, Kim JH, Yoon CM, Koh GY, Kim YK, Gho YS (2010) Outer membrane vesicles derived from Escherichia coli induce systemic inflammatory response syndrome. PLoS One 5(6):e11334. https://doi.org/10.1371/journal.pone.0011334
Pfalzgraff A, Heinbockel L, Su Q, Gutsmann T, Brandenburg K, Weindl G (2016) Synthetic antimicrobial and LPS-neutralising peptides suppress inflammatory and immune responses in skin cells and promote keratinocyte migration. Sci Rep 6:31577. https://doi.org/10.1038/srep31577
Pfalzgraff A, Heinbockel L, Su Q, Brandenburg K, Weindl G (2017) Synthetic anti-endotoxin peptides inhibit cytoplasmic LPS-mediated responses. Biochem Pharmacol 140:64–72. https://doi.org/10.1016/j.bcp.2017.05.015
Pfalzgraff A, Barcena-Varela S, Heinbockel L, Gutsmann T, Brandenburg K, Martinez de Tejada G, Weindl G (2018a) Antimicrobial endotoxin-neutralizing peptides promote keratinocyte migration via P2X7 receptor activation and accelerate wound healing in vivo. Br J Pharmacol. https://doi.org/10.1111/bph.14425
Pfalzgraff A, Brandenburg K, Weindl G (2018b) Antimicrobial peptides and their therapeutic potential for bacterial skin infections and wounds. Front Pharmacol 9:281. https://doi.org/10.3389/fphar.2018.00281
Rice TW, Wheeler AP, Bernard GR, Vincent JL, Angus DC, Aikawa N, Demeyer I, Sainati S, Amlot N, Cao C, Ii M, Matsuda H, Mouri K, Cohen J (2010) A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit Care Med 38(8):1685–1694. https://doi.org/10.1097/CCM.0b013e3181e7c5c9
Schuerholz T, Doemming S, Hornef M, Martin L, Simon TP, Heinbockel L, Brandenburg K, Marx G (2013) The anti inflammatory effect of the synthetic antimicrobial peptide 19-2.5 in a murine sepsis model: a prospective randomized study. Crit Care 17(1):R3. https://doi.org/10.1186/cc11920
Serra R, Grande R, Butrico L, Rossi A, Settimio UF, Caroleo B, Amato B, Gallelli L, de Franciscis S (2015) Chronic wound infections: the role of Pseudomonas aeruginosa and Staphylococcus aureus. Expert Rev Anti-Infect Ther 13(5):605–613. https://doi.org/10.1586/14787210.2015.1023291
Shi J, Zhao Y, Wang Y, Gao W, Ding J, Li P, Hu L, Shao F (2014) Inflammatory caspases are innate immune receptors for intracellular LPS. Nature 514(7521):187–192. https://doi.org/10.1038/nature13683
Sierra JM, Fusté E, Rabanal F, Vinuesa T, Viñas M (2017) An overview of antimicrobial peptides and the latest advances in their development. Expert Opin Biol Ther 17(6):663–676. https://doi.org/10.1080/14712598.2017.1315402
Sil D, Heinbockel L, Kaconis Y, Rössle M, Garidel P, Gutsmann T, David SA, Brandenburg K (2013) Biophysical mechanisms of the neutralization of endotoxins by lipopolyamines. Open Biochem J 7:82–93. https://doi.org/10.2174/1874091X01307010082
Tabah A, Koulenti D, Laupland K, Misset B, Valles J, Bruzzi de Carvalho F, Paiva JA, Cakar N, Ma X, Eggimann P, Antonelli M, Bonten MJ, Csomos A, Krueger WA, Mikstacki A, Lipman J, Depuydt P, Vesin A, Garrouste-Orgeas M, Zahar JR, Blot S, Carlet J, Brun-Buisson C, Martin C, Rello J, Dimopoulos G, Timsit JF (2012) Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT international cohort study. Intensive Care Med 38(12):1930–1945. https://doi.org/10.1007/s00134-012-2695-9
Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, Ouellette M, Outterson K, Patel J, Cavaleri M, Cox EM, Houchens CR, Grayson ML, Hansen P, Singh N, Theuretzbacher U, Magrini N, Aboderin AO, Al-Abri SS, Awang Jalil N, Benzonana N, Bhattacharya S, Brink AJ, Burkert FR, Cars O, Cornaglia G, Dyar OJ, Friedrich AW, Gales AC, Gandra S, Giske CG, Goff DA, Goossens H, Gottlieb T, Guzman Blanco M, Hryniewicz W, Kattula D, Jinks T, Kanj SS, Kerr L, Kieny M-P, Kim YS, Kozlov RS, Labarca J, Laxminarayan R, Leder K, Leibovici L, Levy-Hara G, Littman J, Malhotra-Kumar S, Manchanda V, Moja L, Ndoye B, Pan A, Paterson DL, Paul M, Qiu H, Ramon-Pardo P, Rodríguez-Baño J, Sanguinetti M, Sengupta S, Sharland M, Si-Mehand M, Silver LL, Song W, Steinbakk M, Thomsen J, Thwaites GE, van der Meer JWM, Van Kinh N, Vega S, Villegas MV, Wechsler-Fördös A, Wertheim HFL, Wesangula E, Woodford N, Yilmaz FO, Zorzet A (2018) Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 18(3):318–327. https://doi.org/10.1016/s1473-3099(17)30753-3
Vanaja SK, Russo AJ, Behl B, Banerjee I, Yankova M, Deshmukh SD, Rathinam VA (2016) Bacterial outer membrane vesicles mediate cytosolic localization of LPS and caspase-11 activation. Cell 165(5):1106–1119. https://doi.org/10.1016/j.cell.2016.04.015
Werner S, Grose R (2003) Regulation of wound healing by growth factors and cytokines. Physiol Rev 83(3):835–870. https://doi.org/10.1152/physrev.2003.83.3.835
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Correa, W. et al. (2019). Synthetic Anti-lipopolysaccharide Peptides (SALPs) as Effective Inhibitors of Pathogen-Associated Molecular Patterns (PAMPs). In: Matsuzaki, K. (eds) Antimicrobial Peptides. Advances in Experimental Medicine and Biology, vol 1117. Springer, Singapore. https://doi.org/10.1007/978-981-13-3588-4_8
Download citation
DOI: https://doi.org/10.1007/978-981-13-3588-4_8
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-13-3587-7
Online ISBN: 978-981-13-3588-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)